☰

Non-Small Cell Lung Cancer Clinical Trials

Last reviewed: November 15, 2026

Start with your stage, tumor subtype, exact biomarker result and prior treatment. A first-line metastatic trial, a trial after an EGFR inhibitor, and a study around surgery may enroll very different people—even when they use the same drug.

Answer a few questions to find clinical trials matched to your specific Non-Small Cell Lung Cancer situation.

A thorough search takes ~15 minutes — we'll email your results. No sign-up.

Find matching trials →

Start With Stage, Histology and Prior Treatment

Current Clinical Trial Landscape

Registry snapshot, November 15, 2026: a worldwide ClinicalTrials.gov search for Non-Small Cell Lung Cancer, interventional studies, overall status Recruiting returned 1,089 records. This broad search result is not the number suitable for one person. Open the filtered registry search.

Selected research includes targeted therapies, ADCs, immunotherapy combinations, vaccines, radiation and local treatment. These categories overlap; no fresh class-specific totals are claimed.

Biomarker Results Are Not Interchangeable

Ask your oncology team which tumor or blood tests are appropriate and whether further testing is needed. NCI explains biomarker testing and its limits; no single test guarantees a matching treatment or captures every relevant result. ASCO guidance distinguishes multigene testing from protein-expression assays.

EGFR Exon 20: Approved Treatment and Research Settings

Trial participation is separate from approved treatment. U.S. FDA examples include amivantamab with carboplatin/pemetrexed first-line for locally advanced or metastatic EGFR exon 20 insertion NSCLC, and sunvozertinib after progression on or after platinum chemotherapy (accelerated approval). These indications do not establish adjuvant approval; the surgery-related studies below are research. Discuss current local labels and standard-care alternatives with your oncologist.

Have your stage and biomarker reports ready?

Find Matching Trials

Selected Trials by Biomarker and Treatment Setting

All 77 cited registry records were checked November 15, 2026: 71 recruiting, three not yet recruiting, and three active but not recruiting. All examples below have a phase and dated recruitment label. The six non-enrolling studies are separated at the end. An overall recruiting label does not guarantee that a local site or specific cohort is open, or that you are eligible.

EGFR first-line advanced or metastatic disease

EGFR after prior TKI treatment

EGFR exon 20 insertion and selected uncommon-mutation studies

EGFR resectable, postoperative or limited-metastatic settings

KRAS G12C first-line advanced or metastatic disease

Other advanced KRAS and RAS-mutant studies

KRAS G12C postoperative or post-chemoradiation studies

ALK and ROS1 rearrangements

HER2 mutation-selected studies

HER2 protein-overexpression-selected study

MET exon 14 and BRAF basket studies

First-line immunotherapy and combinations in advanced disease

Previously treated advanced disease: ADC, immunotherapy and gene-therapy approaches

Unresectable stage III or other locally advanced inoperable settings

Resectable and postoperative immunotherapy or vaccine studies

Studies not open to new enrollment

Not yet recruiting means enrollment has not opened; active, not recruiting means ongoing treatment or follow-up without new enrollment. Check the current record and study team before making travel or treatment plans.

Drug Names and Mechanisms

QL1706 is a mixture of two antibodies targeting PD-1 and CTLA-4, rather than a single bispecific antibody. Sigvotatug vedotin is an integrin beta-6-directed ADC; it is not the PD-L1 ADC PF-08046054/SGN-PDL1V in NCT07144280. Drug target, trial biomarker and proven treatment benefit are separate questions.

Rilvegostomig, ivonescimab and other checkpoint combinations have different mechanisms, populations and evidence. A response rate from one study is not a reliable comparison with another regimen. See the checkpoint-combination guide, TROP2 ADC guide, HER2 ADC guide and intismeran evidence guide.

Frequently Asked Questions

How do I find NSCLC trials for my stage and biomarker?

Bring your pathology, stage and latest scans, original mutation/fusion and protein-test reports, and exact prior treatments with dates and progression history. ClinTrialFinder suggests studies for discussion; a trial team confirms protocol eligibility and site availability.

How many NSCLC trials are recruiting?

The November 15, 2026 worldwide ClinicalTrials.gov query for Non-Small Cell Lung Cancer, interventional studies and Recruiting status returned 1,089 records. This is a broad registry search, not a personalized count. Of the 77 selected records on this page, 71 were recruiting; six were not open to new enrollment.

Are first-line trials available for advanced NSCLC?

Yes, selected examples include first-line targeted combinations for defined EGFR, ALK or KRAS groups and immunotherapy-based studies with histology, PD-L1 and driver-alteration restrictions. First-line metastatic treatment differs from treatment before or after surgery and from stage III consolidation.

Does an EGFR trial include all EGFR mutations?

No. Classical exon 19 deletion/L858R, exon 20 insertions and uncommon PACC mutations can have different eligibility requirements. Prior TKI exposure and resistance findings also matter. Read the specific variant and treatment-setting criteria rather than assuming EGFR-positive is enough.

Are HER2 mutation, HER2 expression and MET results equivalent?

No. HER2 activating mutation and HER2 IHC overexpression select different studies. MET exon 14 skipping, MET amplification and c-Met protein expression are also distinct. NCT07005102, for example, is first-line EGFR-mutant disease with c-Met IHC testing, not a general post-osimertinib MET-amplified cohort.

Can someone who already had surgery enter an adjuvant or vaccine trial?

It depends on the protocol. INTerpath-009 (NCT06623422) starts with previously untreated resectable disease and includes neoadjuvant treatment and surgery before postoperative randomization for residual disease. V940-014 (NCT07513376) instead studies selected high-risk stage I disease after surgery. The label adjuvant alone does not establish an entry route.

Find Lung Cancer Trials Matched to Your Situation

Enter your mutation type, PD-L1 status, and treatment history to get AI-matched trial results in minutes.

Find Matching Trials